Corticosteroid News and Research

RSS

Corticosteroids are any steroid hormones made in the adrenal cortex (the outer part of the adrenal gland). They are also made in the laboratory. Corticosteroids have many different effects in the body, and are used to treat many different conditions. They may be used as hormone replacement, to suppress the immune system, and to treat some side effects of cancer and its treatment. Corticosteroids are also used to treat certain lymphomas and lymphoid leukemias.

AGA's new clinical guideline to help manage patients with mild-to-moderate ulcerative colitis

Most patients with ulcerative colitis have mild-to-moderate disease characterized by periods of activity or remission, but practice variations exist in disease management.

10 Jan 2019

Potential combination therapy against rare disease of the bone marrow could improve treatment

Myelofibrosis is a severe and very rare hematological disease for which treatment has only been partially effective to date. Its low incidence rate is one of the reasons why effective therapies are still lacking.

19 Dec 2018

Pooled analysis of Intersect ENT's steroid releasing implants in patients after frontal sinus surgery to be published

Intersect ENT, Inc., a company dedicated to transforming care for patients with ear, nose and throat conditions, today announced publication of a pooled analysis in the International Forum of Allergy & Rhinology, the official journal of the American Rhinologic Society, of the company's PROPEL Contour and PROPEL Mini steroid-releasing sinus implants showing improved outcomes of frontal sinus surgery.

16 Nov 2018

How to avoid shoulder injury related to vaccine administration

A study by researchers at the University of Waterloo reiterates the need for health care professionals, including pharmacists, to take certain precautions to minimize the risk of their patients suffering shoulder injury related to vaccine administration

24 Oct 2018

Genentech’s combination therapy improves outcome in patients with non-squamous non-small cell lung cancer

Genentech, a member of the Roche Group, today announced positive results from the Phase III IMpower130 study of Tecentriq (atezolizumab) plus chemotherapy (carboplatin and Abraxane® [albumin-bound paclitaxel; nab-paclitaxel]) for the initial (first-line) treatment of people with previously untreated metastatic non-squamous non-small cell lung cancer.

22 Oct 2018

Combination of Opdivo and Yervoy shows four-year survival benefits in patients with advanced melanoma

Bristol-Myers Squibb Company today announced four-year data from the Phase 3 CheckMate -067 clinical trial - the longest follow-up to date - which continues to demonstrate durable, long-term survival benefits with the first-line combination of Opdivo (nivolumab) and Yervoy (ipilimumab), versus Yervoy alone, in patients with advanced melanoma.

22 Oct 2018

Merck presents MK-1454 Phase 1 data for treatment of advanced solid tumors or lymphomas

Merck, known as MSD outside the United States and Canada, today announced the first presentation of preliminary data from a Phase 1 clinical trial evaluating MK-1454, an investigational STING (stimulator of interferon genes) agonist, as monotherapy and in combination with KEYTRUDA (pembrolizumab), Merck's anti-PD-1 therapy, in patients with advanced solid tumors or lymphomas.

22 Oct 2018

Takeda presents vedolizumab phase 3 VISIBLE 1 trial results for treatment of moderately to severely active ulcerative colitis

Takeda Pharmaceutical Company Limited today announced results from the phase 3 VISIBLE 1 clinical trial evaluating the efficacy and safety of an investigational subcutaneous formulation of the gut-selective biologic vedolizumab for maintenance therapy in adult patients with moderately to severely active ulcerative colitis who achieved clinical response* at week 6 following two doses of open-label vedolizumab intravenous induction therapy.

22 Oct 2018

Merck presents KEYNOTE-057 trial results for patients with high-risk non-muscle invasive bladder cancer

Merck, known as MSD outside the United States and Canada, today announced the first presentation of results from an interim analysis of KEYNOTE-057, a Phase 2 trial evaluating KEYTRUDA, Merck's anti-PD-1 therapy, for previously treated patients with high-risk non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ or CIS plus papillary disease (Cohort A).

22 Oct 2018

Disruption in combination inhaled corticosteroid therapy may impact patients' symptoms and disease control

Disruption of the refill of patients' regular combination inhaled corticosteroid therapy brand may have impacted symptoms and disease control and potentially lead to an increased rate of costly exacerbations and hospitalizations.

2 Oct 2018

Phase 3 ECHELON-2 clinical trial evaluating ADCETRIS plus CHP meets primary endpoint

Seattle Genetics, Inc. and Takeda Pharmaceutical Company Limited announced today that the phase 3 ECHELON-2 clinical trial met its primary endpoint.

1 Oct 2018

ADCETRIS drug receives approval in Japan as frontline treatment option for Hodgkin lymphoma

Seattle Genetics, Inc. today announced that its collaborator, Takeda Pharmaceutical Company Limited, has received approval from the Japanese Ministry of Health, Labour and Welfare for ADCETRIS (brentuximab vedotin) in combination with doxorubicin, vinblastine and dacarbazine as a frontline treatment option for CD30-positive Hodgkin lymphoma patients in Japan.

24 Sep 2018

CHMP issues positive opinion supporting use of Trelegy Ellipta in broader group of COPD patients

GlaxoSmithKline plc and Innoviva, Inc. announced that the European Medicines Agency's Committee for Medicinal Products for Human Use has issued a positive opinion today supporting the use of Trelegy Ellipta in a broader group of patients with moderate to severe chronic obstructive pulmonary disease and that labeling, if approved, will be updated to further reflect its effect on exacerbations of COPD.

21 Sep 2018

Study reveals promising new drug candidate to treat acute renal failure

A protein produced by the human body appears to be a promising new drug candidate to treat conditions that lead to acute renal failure. This is shown by a study conducted at São Paulo State University in São José do Rio Preto, Brazil.

20 Sep 2018

FDA approves Teva’s AJOVY injection for preventive treatment of migraine in adults

Teva Pharmaceutical Industries Ltd. today announced that the U.S. Food and Drug Administration has approved AJOVY injection for the preventive treatment of migraine in adults.

17 Sep 2018

Inhaled steroid use linked to greater risk of NTM lung infections

Patients using inhaled steroids to control asthma and other breathing problems may be at greater risk for developing nontuberculous mycobacteria lung infections, according to new research published online in the Annals of the American Thoracic Society.

17 Sep 2018

FDA approves new treatment for people with hairy cell leukemia

AstraZeneca and MedImmune, its global biologics research and development arm, announced today that the US Food and Drug Administration has approved LUMOXITI (moxetumomab pasudotox-tdfk) for the treatment of adult patients with relapsed or refractory hairy cell leukemia who have received at least two prior systemic therapies, including treatment with a purine nucleoside analog.

14 Sep 2018

Researchers develop new wearable photostimulator that speeds up hair growth

Although some people embrace the saying "bald is beautiful," for others, alopecia, or excessive hair loss, can cause stress and anxiety.

12 Sep 2018

Pfizer terminates clinical studies evaluating domagrozumab for treatment of Duchenne muscular dystrophy

Pfizer Inc. announced today that it is terminating two ongoing clinical studies evaluating domagrozumab (PF-06252616) for the treatment of Duchenne muscular dystrophy (DMD): a Phase 2 safety and efficacy study (B5161002) and an open-label extension study (B5161004).

30 Aug 2018

EC grants marketing authorization for ONPATTRO (patisiran) in Europe

Alnylam Pharmaceuticals, Inc., the leading RNAi therapeutics company, announced today that the European Commission (EC) has granted marketing authorization for ONPATTRO (patisiran) for the treatment of hereditary transthyretin-mediated (hATTR) amyloidosis in adults with stage 1 or stage 2 polyneuropathy.

30 Aug 2018

Corticosteroid News and Research

AGA's new clinical guideline to help manage patients with mild-to-moderate ulcerative colitis

Potential combination therapy against rare disease of the bone marrow could improve treatment

Pooled analysis of Intersect ENT's steroid releasing implants in patients after frontal sinus surgery to be published

How to avoid shoulder injury related to vaccine administration

Genentech’s combination therapy improves outcome in patients with non-squamous non-small cell lung cancer

Combination of Opdivo and Yervoy shows four-year survival benefits in patients with advanced melanoma

Merck presents MK-1454 Phase 1 data for treatment of advanced solid tumors or lymphomas

Takeda presents vedolizumab phase 3 VISIBLE 1 trial results for treatment of moderately to severely active ulcerative colitis

Merck presents KEYNOTE-057 trial results for patients with high-risk non-muscle invasive bladder cancer

Disruption in combination inhaled corticosteroid therapy may impact patients' symptoms and disease control

Phase 3 ECHELON-2 clinical trial evaluating ADCETRIS plus CHP meets primary endpoint

ADCETRIS drug receives approval in Japan as frontline treatment option for Hodgkin lymphoma

CHMP issues positive opinion supporting use of Trelegy Ellipta in broader group of COPD patients

Study reveals promising new drug candidate to treat acute renal failure

FDA approves Teva’s AJOVY injection for preventive treatment of migraine in adults

Inhaled steroid use linked to greater risk of NTM lung infections

FDA approves new treatment for people with hairy cell leukemia

Researchers develop new wearable photostimulator that speeds up hair growth

Pfizer terminates clinical studies evaluating domagrozumab for treatment of Duchenne muscular dystrophy

EC grants marketing authorization for ONPATTRO (patisiran) in Europe

How Patch Clamp Technology Can Benefit Ion Channel Research

Training Students to use Imaging Techniques: NMR and EPR

High Quality Purification of Proteins Through Liquid Chromatography

Latest News